BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
See today's BioWorld
Home
» Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion
To read the full story,
subscribe
or
sign in
.
Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion
April 21, 2008
By
Catherine Hollingsworth
A Phase II trial of the ACC-011 compound for Alzheimer's disease being developed by Elan Corp. plc and Wyeth Pharmaceuticals has been suspended due to a skin lesion observed in a single patient. (BioWorld Today)
BioWorld
